Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP
Facility
(URL if available)
Clinical Trials
Disease Focus
Cancer/ Hematology
Burnaby Hospital
Regional Cancer
Centre (http://
research.fraserhealth.
ca/clinical_trials/
clinical_trials_research_groups/)
Hematology Research
and Clinical
Trials Unit (HRCTU)
(www.leukemiabmtprogram.org)
•
Hematology Research
Group (www.
providencehealthcare.
org/Dept_of_Medicine/researchers.
html)
Centre for the
Southern Interior
CTU
Edward Miller Clinical
Research Unit
(www.bccancer.bc.ca/
RS/FraserValleyCentre/research.htm)
•
Medical Oncology,
Vancouver Centre
CTU
Novel agents,
expanded access,
and supportive care
studies
All hematologic
malignancies and
also works with stem
cells
Myelodysplastic
syndromes,
acute and chronic
myeloid leukemias,
chronic lymphocytic
leukemia, idiopathic
thrombocytopenic
purpura, lymphoma
in HIV patients, hemophilia,
thrombosis
All cancer types:
radiation, systemic,
and palliative care
All cancer types:
radiation, systemic,
and palliative care
All cancer types (especially
breast, GU,
lung, GI, lymphoma)
Types
of
Trials*
Annual
Patient
Accrual
II, III Sees
approx.
500
new
patients/
yr
I, II, III Approx.
100
Hospital/
Agency
(Health
Authority)*
Burnaby
Hospital
(FH)
N/A N/A St. Paul’s
(Providence)
I, II, III Approx.
150
Primarily
II, III;
limited
I; occasional
010 , I,
II, III
Investigators Contact
9
• Lam, Wendy Tkachuk, Ryan. Research
Coordinator: T: 604-836-
5340.
tkservices@shaw.ca.
VGH (VCH) • 12 investigators
as listed in Appendix
1
BCCA-Centre
for the
Southern
Interior
(Kelowna)
(PHSA)
70 BCCA - Fraser
Valley Centre
(Surrey)
(PHSA)
400 BCCA-
Vancouver
Centre
(PHSA)
5, including:
• Vickars, Linda
• Leitch, Heather
• 16 investigators
as listed in Appendix
1
• 10 investigators
as listed in Appendix
1
• 27 investigators
as listed in Appendix
1
Smith, Clay. Director
Leukemia/BMT Program
of B.C.
T: 604-875-4863.
clsmith@bccancer.bc.ca.
Leitch, Heather. Director.
Tel: 604 684-5794.
hleitch@providencehematology.com.
Broughton, Sandra
Regional Administrator.
T: 250-712-3903.
sbroughton@bccancer.
bc.ca.
Lee, Christopher
Medical Director.
T: 604-930-4017.
clee@bccancer.bc.ca.
Chi, Kim. Director.
T: 604-877-6000 x 2746.
kchi@bccancer.bc.ca.
10 Phase 0 is a recent designation for exploratory, first-in-human trials conducted in accordance with the U.S. FDA 2006 Guidance on
Exploratory Investigational New Drug (IND) Studies. Phase 0 trials are also known as human microdosing studies. Distinctive features
of Phase 0 trials include the administration of single subtherapeutic doses of the study drug to a small number of subjects (10 to 15)
to gather preliminary data on the agent’s pharmacokinetics and pharmacodynamics. Drug development companies carry out Phase
0 studies to rank drug candidates to take forward into further development.